$15.9M Private Placement Closes for Longeveron, Potential $15M More Contingent on Milestones
Summary
Longeveron Inc. has successfully closed the initial tranche of its private placement, securing $15.9 million through the sale of common and convertible preferred stock at $0.52 per share. This financing also includes a potential second tranche of $15 million, contingent upon achieving a key HLHS Phase 2b milestone and meeting certain trading thresholds. This capital raise follows the company's recent announcement of Nasdaq non-compliance and a proposed reverse stock split, highlighting a critical need for funding. The $15.9 million infusion is highly material, representing nearly 100% of Longeveron's current market capitalization, and is intended to fund laromestrocel development and general working capital. While providing crucial liquidity, this significant raise will also result in substantial dilution for existing shareholders. Traders should monitor the company's progress on the HLHS Phase 2b milestone and its efforts to regain Nasdaq compliance.
At the time of this announcement, LGVN was trading at $0.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.3M. The 52-week trading range was $0.48 to $1.92. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: Wiseek News.